The Organizing Committee  is delighted to invite you to attend the 7th European Biosimilars Congress  one of its remarkable Pharmaceutical conferences, to be held during May 15-17, 2017 in Munich, Germany. European Biosimilars Congress 2017 brings together scientists, researchers and CROs from around the world. With the approval of second biosimilar by the USFDA-Inflectra the biosimilars market is owned to experience a exponential growth over the coming few years. Many biologics products are making their entry in the pharma market and experiencing a notable rise in their usage over the conventional medications.

At Euro Biosimilars 2017 meet your target audiences from around the world focused on learning about biologics and biosimilars. This conference would be your single best opportunity to reach the largest assemblage of participants from the biologics and biosimilars community.

Why to attend???

Conduct demonstrations, distribute information, meet with current and potential Scientists to update yourself with latest technological advancememts and new research, and receive name recognition at this 3-days' event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in the era of follow-on-biologics and biosimilars are hallmarks of this conference.

Target Audience:

• Directors, CEO’s of Organizations

• Business Development Managers

• Chief Scientific Officers

• R&D Researchers from Biosimilar and Bioslogics Industries

• Professors, Associate Professors, Assistant Professors

• PhD Scholars

• Patent Attorneys

• Intellectual Property Attorneys

• Investment Analysts

• Association, Association presidents and professionals

• Noble laureates in Health Care and Medicine

• Bio instruments Professionals

• Bio-informatics Professionals

• Software development companies

• Research Institutes and members

• Supply Chain companies

• Manufacturing Companies

• CRO and DATA management Companies

• Training Institutes

• Business Entrepreneurs

Market Analysis
As per market researchers, the global biosimilar market is expected to be worth $24 billion in 2019-at compound annual growth rate (CAGR) of some 65% from 2014.Clinical trials at global level would incur an approximate cost of few hundred crores.The estimated cost of developing biosimilars for global markets is $75-250 million, while developing traditional non-biologic generics costs about $2-3 million. With the introduction of Inflectra on April 06, 2016 the Biosimilar Market will grow at even higher rate.

Critical Analysis:

The capital-intensive nature of the biosimilar business and long gestation periods between initial investment and commercialization require biosimilar players to take a higher level of risk than their counterparts in the smallmolecule generics business, and this can be a significant barrier to entry for many start-ups.

Importance & Scope:

The European-based pharmaceutical industry makes a major contribution to the Europe, not just in financial terms but also in terms of high-trait employment. Globally Pharma Market ranges from $870-$900 billion and in Europe $260-$280 billion.

All accepted abstracts will be published in respective Conferenceseries International Journals.